Business Description
Lantheus Holdings Inc
NAICS : 325411
SIC : 2834
ISIN : US5165441032
Total Employee Number:
1,193Compare
Compare
Traded in other countries / regions
LNTH.USA0L8.Germany1LNTH.Italy Index Membership
Russell 2000Russell 3000 IPO Date
2015-06-25Description
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.95 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.48 | |||||
Debt-to-EBITDA | 1.33 | |||||
Interest Coverage | 15.26 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 5.6 | |||||
Beneish M-Score | -2.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 19.4 | |||||
3-Year EBITDA Growth Rate | 72 | |||||
3-Year EPS without NRI Growth Rate | 12.9 | |||||
3-Year FCF Growth Rate | 11 | |||||
3-Year Book Growth Rate | 36.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.94 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.67 | |||||
9-Day RSI | 50.17 | |||||
14-Day RSI | 47.77 | |||||
3-1 Month Momentum % | -1.66 | |||||
6-1 Month Momentum % | 29.89 | |||||
12-1 Month Momentum % | 87.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.06 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 1.77 | |||||
Days Inventory | 36.22 | |||||
Days Sales Outstanding | 82.33 | |||||
Days Payable | 28.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 2.96 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 60.14 | |||||
Operating Margin % | 19.43 | |||||
Net Margin % | 17.69 | |||||
EBITDA Margin % | 30.28 | |||||
FCF Margin % | 24.92 | |||||
OCF Margin % | 26.52 | |||||
ROE % | 23.33 | |||||
ROA % | 12.09 | |||||
ROIC % | 14.97 | |||||
3-Year ROIIC % | 24.05 | |||||
ROC (Joel Greenblatt) % | 118.17 | |||||
ROCE % | 19.63 | |||||
Years of Profitability over Past 10-Year | 8 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.39 | |||||
Forward PE Ratio | 15.92 | |||||
PE Ratio without NRI | 18.62 | |||||
Shiller PE Ratio | 45.86 | |||||
Price-to-Owner-Earnings | 17.75 | |||||
PS Ratio | 4.34 | |||||
PB Ratio | 5.02 | |||||
Price-to-Tangible-Book | 17.2 | |||||
Price-to-Free-Cash-Flow | 17.39 | |||||
Price-to-Operating-Cash-Flow | 16.34 | |||||
EV-to-EBIT | 17.3 | |||||
EV-to-Forward-EBIT | 21.59 | |||||
EV-to-EBITDA | 14.05 | |||||
EV-to-Forward-EBITDA | 13.43 | |||||
EV-to-Revenue | 4.25 | |||||
EV-to-Forward-Revenue | 3.56 | |||||
EV-to-FCF | 17.07 | |||||
Price-to-GF-Value | 1.11 | |||||
Price-to-Projected-FCF | 1.41 | |||||
Price-to-Median-PS-Value | 1.41 | |||||
Price-to-Graham-Number | 3.77 | |||||
Earnings Yield (Greenblatt) % | 5.78 | |||||
FCF Yield % | 5.89 | |||||
Forward Rate of Return (Yacktman) % | -33.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LNTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lantheus Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1,556.313 | ||
| EPS (TTM) ($) | 4.14 | ||
| Beta | 0.0841 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.63 | ||
| Volatility % | 30.03 | ||
| 14-Day RSI | 47.77 | ||
| 14-Day ATR ($) | 1.048986 | ||
| 20-Day SMA ($) | 100.72275 | ||
| 12-1 Month Momentum % | 87.87 | ||
| 52-Week Range ($) | 49.67 - 111.86 | ||
| Shares Outstanding (Mil) | 65.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lantheus Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lantheus Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:00 | In 173 days | ||
| Annual report for 2026 | 2027-02-26 | In 172 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 172 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 60 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 101.50 (+0.34%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:40 | 100.01 (-1.50%) | ||
| William Blair 46(th) Annual Growth Stock Conference | 2026-06-03 12:10 | 96.30 (-0.86%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:00 | 86.15 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 86.15 (+0.00%) |
Show
Entries
Lantheus Holdings Inc Frequently Asked Questions
What is Lantheus Holdings Inc(LNTH)'s stock price today?
The current price of LNTH is $100.96. The 52 week high of LNTH is $111.86 and 52 week low is $49.67.
When is next earnings date of Lantheus Holdings Inc(LNTH)?
The next earnings date of Lantheus Holdings Inc(LNTH) is 2026-11-06 Est..
Does Lantheus Holdings Inc(LNTH) pay dividends? If so, how much?
Lantheus Holdings Inc(LNTH) does not pay dividend.
Guru Commentaries on NAS:LNTH
Carmignac Investissement
Bullish
2026 Q2
What the manager wrote
Lantheus, a diagnostic-imaging specialist focused on radiopharmaceuticals, particularly for prostate cancer detection, performed well. The company is positioned in a growing sector with significant demand for its innovative imaging solutions, which enhances its competitive advantage. The strong performance of Lantheus reflects its ability to capitalize on the increasing need for advanced diagnostic tools in healthcare, indicating a positive outlook for its future growth.
Polaris Global Equity
Bullish
2026 Q1
1Q2026global
Polaris Wealth Advisory Group, LLC
· 169 holdings
What the manager wrote
Lantheus Holdings Inc. gained after earnings beat expectations and the FDA approved a new formulation for its PSMA PET imaging agent, Pylarify. This approval is a significant milestone that enhances the company's product offering and positions it for future growth in the healthcare sector. The positive earnings report indicates strong operational performance, suggesting that Lantheus is well-positioned to capitalize on its advancements in imaging technology.
Press Release
Articles on Lantheus Holdings Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers